Two thirds of the laboratories do not plan to invest in France in the coming 3 years, reveals the annual leem barometer

Several brakes are mentioned: prices of drugs deemed too low, administrative slowness and taxation deemed “illegible and punitive”.

It is one of the French paradoxes. France is still the 2nd pharmaceutical market in Europe, while becoming one of the least attractive for laboratories. “64% of leaders no longer consider investing in France in the next three years”According to the annual barometer published Tuesday by Leem, professional organization of drug companies which brings together 280 members.

In detail, seven large laboratories out of 10 and one in two SMEs say they are cautious about investing in France in the coming years. And more than nine out of 10 managers questioned believe that the level of attractiveness has dropped. How to explain this dropout? Several obstacles are pointed out by the sector: the lack of visibility, the price of the drug in very supervised France or the time for sale on the market.

The secretary of the Leem office explains to France Culture that political and fiscal instability in France is an obstacle. “To invest in a factory, you must have visibility in the coming years”, Recalls Clarisse Lhoste, also president of the French subsidiary of the American MSD, one of the five ‘Big Pharma’. “If the economic conditions change, if a new tax is invented, necessarily the leaders of subsidiaries in France have trouble defending investments with our mother -in -law to come and invest in France compared to Germany, Italy, China or elsewhere”, she supports.

Another obstacle is the price of medication 11 to 16% cheaper than the European average. Now it’s this “which determines the attractiveness of a country”According to the sector representative. For the Leem, it is also urgent to act on the time of access to the reimbursed market which are very long, 523 days in France against 50 in Germany. “In Germany, they can market the day after the marketing authorization”, Salues ​​Corinne Blachier-Poisson, who heads the Leem access commission, “So the products are immediately accessible to patients”.

Today, “Only 60% of drugs with European marketing authorization are available in France” AND “Only 9% of new drugs sold in Europe are manufactured in France, while our country could produce much more”also underlines the barometer. Professional organization therefore launches an appeal for “Activate the levers of attractiveness in emergency”, Recalling that a euro invested in France in the drug generates 2.10 euros in wealth.

To redo a France a “Innovation reception land” and investors, the pharmaceutical sector requires “Display” of a taxation deemed “illegible and punitive”. Leem offers in particular to review and harmonize the fixing of drug prices and create tax incentives to improve the operating conditions of industrial sites. The megaping of drug companies also requires “A health programming law, carried by stable inter -ministerial piloting”, To achieve health sovereignty presented as one of the government’s priorities.

Methodology : The 360 ​​° 2025 barometer of France’s attractiveness for the pharmaceutical industry was produced by PWC Strategy &. 49 Leem adhering medication companies have responded, they represent 71% of industry turnover in France.